Research study Program year 2025 Source: CMS Open Payments

A Phase 1, Randomized, Placebo-Controlled, Double-Blind, Parallel-Grou

Research payments

$3,240,090

35 payments

Through program year 2025, $3,240,090 in research payments was reported against A Phase 1, Randomized, Placebo-Controlled, Double-Blind, Parallel-Grou, across 35 payments, paid by GlaxoSmithKline, LLC..

Paid by: GlaxoSmithKline, LLC.
ClinicalTrials.gov: No trial number was reported for this study

By program year

1 row

Year	Kind	Amount	Payments
2025	Research	$3,240,090	35

Breakdown

Who paid Research payments · program year 2025

GlaxoSmithKline, LLC. $3,240,090 35 payments

Who received the money Research payments · program year 2025

Ppd Development LP Organisation paid for research $2,424,778 15 payments
Altasciences Professional Los Angeles Pc Organisation paid for research $815,312 20 payments

Usually the institution or organisation running the study, not a person.

Records

Every payment, record by record

Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.

Principal investigators named

2 shown

Named on the study's payments. Being named is not being paid: the money in the figures above went to the recipients listed, not necessarily to these people.

What you are looking at

Research payments are tied to a study. Being named on a study as a principal investigator is reported separately from being paid as a recipient, and the two are not the same thing — a named investigator has not necessarily received the money.